Document is current
Any future updates will be listed below
-
Authors
Ebrahimpour, Afshin
Wang, Min
Li, Li
Jegga, Anil G.
Bonnen, Mark D.
Eissa, N. Tony
Raghu, Ganesh
Jyothula, Soma
Kheradmand, Farrah
Hanania, Nicola A.
Rosas, Ivan O.
Ghebre, Yohannes T. http://orcid.org/0000-0002-2144-8600
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (K01HL118683, R01HL137703, T32HL007747-22)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R56AR077445)
American Heart Association (17GRNT33460159)
Cancer Prevention and Research Institute of Texas (RP190497)
- License Information
-
More Information
Article History
Received: 19 February 2021
Accepted: 4 May 2021
First Online: 19 May 2021
Declarations
:
: Not applicable.
: All authors consent to the publication of this manuscript.
: YTG is an inventor on patents, owned by Stanford University and Baylor College of Medicine, that protect the use of agents, including proton pump inhibitors (PPIs), for therapeutic use of new indications. MDB is an inventor on the patent application owned by Baylor College of Medicine.
